KalVista Pharmaceuticals (KALV) has released an update.
KalVista Pharmaceuticals has released promising clinical data from its Phase 3 KONFIDENT trial, showcasing significant advancements in treating Hereditary Angioedema (HAE). The trial met all primary and key secondary endpoints, with sebetralstat showing quicker symptom relief and attack resolution compared to placebo, without serious adverse events. This breakthrough is poised to be a highlight at the upcoming American Academy of Allergy Asthma and Immunology annual meeting.
For further insights into KALV stock, check out TipRanks’ Stock Analysis page.
